FDA Approvals, Breakthrough Designations, Priority Reviews, and More

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

The top 5 OncLive TV videos of the week cover insights in endometrial cancer, mCRPC, germ cell tumors, melanoma, and HNSCC.

The FDA received a BLA for etentamig in relapsed/refractory multiple myeloma, based on response and PFS gains in the phase 3 CERVINO trial.

Elranatamab improved PFS vs 3 standard regimens in relapsed/refractory multiple myeloma in the phase 3 MagnetisMM-32 trial.

The top 5 OncLive TV videos of the week cover insights in CRC at ESMO 2026, dMMR rectal cancer, chronic neutropenia, pediatric LGG, and MSS CRC.

Adding intismeran autogene to pembrolizumab cut the risk of recurrence and distant metastasis in resected high-risk melanoma in INTerpath-001.

The FDA approved dostarlimab in rectal cancer and pembrolizumab in tumors with high mutational burden, Europe cleared teclistamab in myeloma, and more.